Zevra Therapeutics Inc (ZVRA) concluded trading on Wednesday at a closing price of $9.07, with 0.43 million shares of worth about $3.92 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 6.96% during that period and on June 18, 2025 the price saw a gain of about 2.95%. Currently the company’s common shares owned by public are about 54.68M shares, out of which, 54.08M shares are available for trading.
Stock saw a price change of -3.30% in past 5 days and over the past one month there was a price change of 1.80%. Year-to-date (YTD), ZVRA shares are showing a performance of 8.75% which increased to 84.73% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $4.20 but also hit the highest price of $9.76 during that period. The average intraday trading volume for Zevra Therapeutics Inc shares is 551.93K. The stock is currently trading 2.05% above its 20-day simple moving average (SMA20), while that difference is up 12.53% for SMA50 and it goes to 11.95% higher than SMA200.
Zevra Therapeutics Inc (NASDAQ: ZVRA) currently have 54.68M outstanding shares and institutions hold larger chunk of about 65.35% of that.
The stock has a current market capitalization of $495.94M and its 3Y-monthly beta is at 1.99. It has posted earnings per share of -$1.89 in the same period. It has Quick Ratio of 2.93 while making debt-to-equity ratio of 1.51. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ZVRA, volatility over the week remained 2.88% while standing at 2.10% over the month.
Stock’s fiscal year EPS is expected to rise by 90.90% while it is estimated to increase by 422.29% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Cantor Fitzgerald on January 08, 2025 offering an Overweight rating for the stock and assigned a target price of $25 to it. Coverage by Guggenheim stated Zevra Therapeutics Inc (ZVRA) stock as a Buy in their note to investors on October 07, 2024, suggesting a price target of $20 for the stock. On September 24, 2024, Maxim Group Reiterated their recommendations, while on September 24, 2024, JMP Securities Initiated their ratings for the stock with a price target of $17. Stock get a Buy rating from Maxim Group on April 02, 2024.
